Experienced Healthcare Company Growing Revenues via a Range of Vital Services Including Mobile Virus Testing Vans: Net Medical Xpress (OTC: NMXS)
– New Mexico Based Healthcare Services Provider with Expanding Business.
– 24/7/365 Call Center, Software Developers and Telemedicine Platforms.
– CLIA Certified Lab that Specializes in Virus Testing and Diagnostics.
– Total Revenue of 821,399 for the Q4 ending on December 31st.
– Mobil Testing Vans Operating in New Mexico with More States to be Added.
– Upper Respiratory Test Identifies COVID, Flu and the Common Cold.
Net Medical Xpress (OTC: NMXS) has two operating units. Net Medical Xpress provides telemedicine solutions for hospitals, nursing homes, specialty hospitals and other medical facilities. NMXS specializes in teleneurology, teleneurosurgery, telecardiology, teleorthopedics, telewoundcare and telenephrology.
NMXS maintains a 24/7/365 call center, software developers, and telemedicine platforms. In additional, Net Medical Labs is a moderate complex CLIA certified lab that specializes in virus testing and diagnostics. NMXS uses bioMerieux’s proprietary PCR testing module that is the only test that can detect 22 separate viral pathogens and has been approved by the FDA. The NMXT mobile fleet of vans is utilized to provide statewide COVID and FLU testing for schools, companies, homeless shelters, and nursing homes. The lab also serves as a reference lab for physician offices, and other facilities that lack services for complex virus diagnostics.
– Preliminary Results for Fourth Quarter 2021
On February 22nd NMXS said that unaudited preliminary numbers show the company recorded net income of $301,285 in the fourth fiscal quarter ending December 31, 2021. Total revenue was $821,399.
NMXS CEO Dick Govatski said, “Demand was high for Covid tests provided through our state-of-the-art mobile testing labs. Our patients benefited from our use of bioMerieux’s proprietary PCR testing module that provides quick certified results that can be used for travel and other purposes. It is the only FDA approved test that can detect and identify 22 separate viral pathogens including Covid, influenza and the common cold.”
– NMXS Upper Respiratory Test Identifies COVID, Flu and the Common Cold; More States to Be Added to Company Range of Operations
On February 16th NMXS said it is providing Gold Standard PCR testing for Covid, ordinary flu, colds and related other upper respiratory infections to the people of New Mexico.
With mobile vans currently operating in Albuquerque and Taos, NMXS now offers bioMerieux’s proprietary PCR testing module that make it quick, inexpensive and easy for those affected to quickly get a definitive idea of the illness they might be facing. Results of the tests are quickly known and instantly made available to appropriate authorities facilitating travel, going to work, job interviews, etc. The initial program has been so successful that NMXS is now planning similar programs for other states.
NMXS CEO Dick Govatski said, “The roll out of our respiratory testing vans has been an enormous success. We have experienced high volumes of those seeking definitive information about their health status.
“Because of the Covid pandemic, people want and need information about the status of their health. Our mobile testing sites are the answer. At the end of December, the CDC expressed concerns about tests that couldn’t distinguish between Covid, traditional influenza or a common cold. We selected bioMerieux’s proprietary PCR testing module because it is the only test that can detect 22 separate viral pathogens and has been cleared by the FDA.”
Now it is easy for those affected to quickly and conveniently obtain definitive knowledge of what they are facing. The process is easy, fast and official. And the tests are free to the public.
“bioMerieux,’s respiratory panel covers multiple targets in a single test accurately detecting and identifying pathogens most commonly associated with upper respiratory infections. If you are planning to travel and you suddenly come down with a cold, it’s important to know whether it’s just a common cold of something more serious,” Govatski said.
NMXS is one of the few companies providing mobile labs along with the software, trained personnel and licensed physicians that enable quick and accurate reporting to federal and state medical authorities.
About bioMerieux — bioMerieux has been a major global player in the field of diagnostics for infectious diseases for more than 55 years. Their websites can be viewed at https://www.biomerieux.com and www.biofiredx.com.
– NMXS Covid Testing on Behalf of New Mexico Department of Health
On February 7th MNXS announced it has begun Covid testing under an agreement with the State of New Mexico Department of Health.
Under the terms of the agreement, NMXS is:
– Providing both rapid antigen and PCR tests at a variety of sites.
– Providing a licensed physician for Covid testing.
– Providing CLIA (Clinical Laboratory Improvement Amendments) certified laboratory facilities to process and analyze test specimens.
– Staffing and equipping a project management hub, laboratory, and mobile testing units with a capacity of 700 persons to be tested per day.
– Providing fully equipped mobile testing teams with a minimum of two persons per team for the region.
– Providing a copy of certified results from our CLIA certification to each person tested.
NMXS Chief Medical Officer (CMO) Dr. Neeraj Dubey, MD said, “We are delighted to be providing COVID testing services for the state of New Mexico. Our mobile testing vans are operating successfully in Albuquerque and Taos. This is an important activity for our company and, ultimately, for our shareholders as it is already contributing to increases in revenue and cash flow.”
NMXS is providing COVID-19 testing at Wilson Stadium in Albuquerque in cooperation with Albuquerque Public Schools and Sagebrush Inn and Suites in Taos as well as other locations.
For more information on Net Medical Xpress (OTC: NMXT) visit www.netmedical.com.
DISCLAIMER: CAP/FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CAP/FPS/CA is NOT affiliated in any manner with any company mentioned herein. CAP/FPS/CA is a news dissemination solutions provider and is NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. CAP/FPS/CA’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. CAP/FPS/ CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CAP/FPS/CA has been compensated $500 by a third party for dissemination of this article.
These news releases and postings may contain forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.